

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI74097

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Termination and Release
CONVEYING PARTY DATA	
Name	Execution Date
North Haven Expansion Credit Fund Holdings LP	03/06/2024
RECEIVING PARTY DATA	
Company Name:	Sanuwave, Inc.
Street Address:	3360 Martin Farm Road, Suite 100
City:	Suwanee
State/Country:	GEORGIA
Postal Code:	30024
PROPERTY NUMBERS Total: 10	
Property Type	Number
Patent Number:	8556813
Patent Number:	9161768
Patent Number:	9522011
Patent Number:	10058340
Patent Number:	10238405
Patent Number:	10639051
Patent Number:	11666348
Application Number:	17064844
Application Number:	17065261
Application Number:	17065054
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(800)221-0102
Email:	ipteam@cogencyglobal.com
Correspondent Name:	Khadijah Sampson
Address Line 1:	1025 Connecticut Ave NW, Suite 712
Address Line 2:	COGENCY GLOBAL INC.
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20036
ATTORNEY DOCKET NUMBER:	2292832 ks

NAME OF SUBMITTER:	Andrew Hackett
SIGNATURE:	Andrew Hackett
DATE SIGNED:	03/06/2024
Total Attachments: 4 source=NH Expansion Credit - Sanuwave - Termination of IP Collateral (2.2024)(Executed)#page1.tif source=NH Expansion Credit - Sanuwave - Termination of IP Collateral (2.2024)(Executed)#page2.tif source=NH Expansion Credit - Sanuwave - Termination of IP Collateral (2.2024)(Executed)#page3.tif source=NH Expansion Credit - Sanuwave - Termination of IP Collateral (2.2024)(Executed)#page4.tif	

TERMINATION AND RELEASE OF
INTELLECTUAL PROPERTY COLLATERAL

This Termination and Release of Intellectual Property Collateral (this "Termination") dated as of March 6, 2024, is executed by **NH EXPANSION CREDIT FUND HOLDINGS LP** ("North Haven Expansion"), as agent (the "Secured Party"), on behalf of the Holders (as defined below), and in favor of **SANUWAUVE, INC.**, a Delaware corporation ("Grantor"). All capitalized terms used in this Termination and not otherwise defined herein, shall have the respective meanings given to such terms in the Intellectual Property Security Agreement (defined below) or the Security Agreement (defined below).

RECITALS

A. Pursuant to the Intellectual Property Security Agreement, dated as of August 6, 2020, executed by Grantor (as amended from time to time, the "Intellectual Property Security Agreement"), which was entered into in conjunction with that certain Note and Warrant Purchase and Security Agreement, dated as of August 6, 2020, between Secured Party, the Holders from time to time signatory hereto, including North Haven Expansion in its capacity as a Holder (each, a "Holder" and collectively, the "Holders"), and Sanuwave Health, Inc., a Nevada corporation (as amended from time to time, the "NWPSA"), and that certain Third Party Security Agreement, dated August 6, 2020, by and among Secured Party, Grantor and the other Grantors from time to time party thereto (as amended from time to time, the "TPSA" and, together with the NSPSA, the "Security Agreement"), Grantor granted to Secured Party a security interest in, among other things, the Patent Collateral (defined below).

B. The Intellectual Property Security Agreement was recorded with the United States Patent and Trademark Office on August 7, 2020 at Reel/Frame 53436/953 and on July 15, 2021 at Reel/Frame 56873/142 to evidence the security interest granted under the Security Agreement.

C. Secured Party agrees to terminate and release its security interest in the Patent Collateral specified below.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Secured Party hereby agrees as follows:

1. Secured Party hereby expressly irrevocably and unconditionally terminates, cancels, discharges and releases such security interest in all right, title and interest of Grantor in any and all Patent Collateral, including, without limitation, all of the following and reassigns, transfers and conveys to Grantor any and all right, title and interest of Secured Party (if any) therein or thereto, including, in each instance, any and all of the foregoing granted to Secured Party pursuant to the Intellectual Property Security Agreement and/or the Security Agreement:

(a) (i) the patents, patent registrations and the applications listed on **Exhibit A**, (ii) inventions and improvements claimed in connection with the foregoing, (iii) renewals, reissues, divisions, continuations, extensions and continuations-in-part of the foregoing (collectively, clauses (i)-(iii) the "**Patents**"), (iv) all income, royalties, damages and payments now or hereafter due or payable under or with respect thereto, including, without limitation, claims for damages and payments for past or future infringements of the Patents, (v) the right to sue for past, present and future infringements of the Patents; (vi) licenses or other rights to use any of the Patents an all license fees and royalties arising from such use to the extent permitted by such license or rights; (vii) amendments, renewals and extensions of any of the Patents; proceeds and products of the Patents, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing; (viii) all rights corresponding of the Patents throughout the world; and (ix) the goodwill of the Grantor's business connected with and symbolized by the Patents (collectively, the "**Patent Collateral**").

2. Secured Party represents and warrants that it has the full power and authority to execute this Termination.

3. Secured Party shall record or file this Termination with the Patent Division of the United States Patent and Trademark Office (at the Grantor's sole cost and expense).

4. Secured Party hereby agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts as may be reasonably necessary to effect the termination, release, or reassignment to the Grantor of the security interest contemplated hereby (at the Grantor's sole cost and expense).

5. New York law governs this Termination without regard to principles of conflicts of law.

[signature on following page]


IN WITNESS WHEREOF, Secured Party has executed and delivered this Termination as of the day and year first above written.

SECURED PARTY:

NH EXPANSION CREDIT FUND HOLDINGS LP

BY: MS EXPANSION CREDIT GP, L.P.
ITS: GENERAL PARTNER

BY: MS EXPANSION CREDIT GP INC.
ITS: GENERAL PARTNER

By: DocuSigned by:
B25D002E1E514B3...

Name: William Reiland

Title: Managing Director

[Signature Page to Termination and Release of Intellectual Property Collateral]

DMS 41737826

PATENT
REEL: 066743 FRAME: 0410

EXHIBIT A**PATENTS**

Title	Publication Date	Patent Number	Publication Number	Application Date	Application Number
Extracorporeal pressure shock wave device	2013-10-15	US8556813	US20110034832	2010-07-08	12/832,932
Extracorporeal pressure shock wave devices with reversed applicators and methods for using these devices	2015-10-20	US9161768	US20140088465	2013-09-25	14/036,461
Shock wave applicator with movable electrode	2016-12-20	US9522011	US20160000645	2015-09-17	14/857,360
Extracorporeal pressure shock wave devices with multiple reflectors and methods for using these devices	2018-08-28	US10058340	US20140243715	2014-05-07	14/272,155
Blood vessel treatment with intracorporeal pressure shock waves	2019-03-26	US10238405	US20160008016	2015-09-25	14/865,744
Occlusion and clot treatment with intracorporeal pressure shock waves	2020-05-05	US10639051	US20160022294	2015-10-05	14/874,650
Intracorporeal expandable shock wave reflector	2023-06-06	US11666348	US20200330113	2020-04-28	16/860,544
SHOCK WAVE APPLICATOR WITH VARIABLE PENETRATION DEPTH	2021-03-25		US20210085349	2020-10-07	17/064,844
DRUG DELIVERY SYSTEM AND METHOD USING SHOCK WAVES	2021-03-25		US20210085350	2020-10-07	17/065,261
SHOCK WAVE APPLICATOR WITH MECHANICAL STIMULATION	2021-04-01		US20210093342	2020-10-07	17/065,054